Italia markets open in 12 minutes

Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0864
+0,0002(+0,02%)
Bitcoin EUR
65.635,59
+3.986,48(+6,47%)
CMC Crypto 200
1.530,27
+41,73(+2,80%)

NBIX May 2024 120.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

15,35

0,00

(0,00%)

In data: 12:03PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat